omeprazole has been researched along with Celiac Sprue in 8 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 9.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 5.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| " This review emphasizes the importance of personalized medicine for individuals with gastroesophageal disorders that require long-term use of PPIs." | 3.01 | A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition. ( Brooks, AE; McMillan, A; Perez, C, 2023) |
| "Celiac disease is an autoimmune enteropathy characterized by an aberrant immune response to ingested gluten in genetically predisposed individuals." | 2.94 | Celiac disease serology and gut microbiome following proton pump inhibitor treatment. ( Abrams, JA; Alaedini, A; Freedberg, DE; Green, PHR; Jang, S; Lebwohl, B, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| McMillan, A | 1 |
| Perez, C | 1 |
| Brooks, AE | 1 |
| Jang, S | 1 |
| Lebwohl, B | 1 |
| Abrams, JA | 1 |
| Green, PHR | 1 |
| Freedberg, DE | 1 |
| Alaedini, A | 1 |
| Veres, G | 1 |
| Korponay-Szabó, I | 1 |
| Maka, E | 1 |
| Glasz, T | 1 |
| Mamula, P | 1 |
| Schuster, V | 2 |
| Tefs, K | 2 |
| Papp, M | 1 |
| Dezsöfi, A | 1 |
| Arató, A | 1 |
| Kloesel, B | 1 |
| Chandan, VS | 1 |
| Alexander, GL | 1 |
| Hershko, C | 1 |
| Hoffbrand, AV | 1 |
| Keret, D | 1 |
| Souroujon, M | 1 |
| Maschler, I | 1 |
| Monselise, Y | 1 |
| Lahad, A | 1 |
| Bruno, MJ | 1 |
| Rauws, EA | 1 |
| Hoek, FJ | 1 |
| Tytgat, GN | 1 |
| Tran, TM | 1 |
| Van den Neucker, A | 1 |
| Hendriks, JJ | 1 |
| Forget, P | 1 |
| Forget, PP | 1 |
| Heijerman, HG | 1 |
| Lamers, CB | 1 |
| Bakker, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Celiac Sprue
| Article | Year |
|---|---|
A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition.
Topics: Celiac Disease; Genetic Predisposition to Disease; Humans; Omeprazole; Proton Pump Inhibitors | 2023 |
3 trials available for omeprazole and Celiac Sprue
| Article | Year |
|---|---|
Celiac disease serology and gut microbiome following proton pump inhibitor treatment.
Topics: Actinomycetales; Adult; Alleles; Celiac Disease; Feces; Female; Gastrointestinal Microbiome; Gastroi | 2020 |
Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy.
Topics: Adult; Aged; Celiac Disease; Cimetidine; Double-Blind Method; Exocrine Pancreatic Insufficiency; Fem | 1994 |
Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis.
Topics: Adult; Capsules; Celiac Disease; Cystic Fibrosis; Double-Blind Method; Drug Interactions; Drug Thera | 1991 |
4 other studies available for omeprazole and Celiac Sprue
| Article | Year |
|---|---|
Duodenal ulceration in a patient with celiac disease and plasminogen I deficiency: coincidence or cofactors?
Topics: Abdominal Pain; Biopsy, Needle; Blood Chemical Analysis; Celiac Disease; Child; Deficiency Diseases; | 2011 |
An unusual referral for epigastric pain, nausea, abdominal bloating, diarrhea, and weight loss.
Topics: Abdominal Pain; Adult; Anti-Ulcer Agents; Biopsy; Celiac Disease; Diarrhea; Diet, Gluten-Free; Duode | 2012 |
Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Antibodies, Bacterial; Autoantibodies | 2005 |
Effects of a proton-pump inhibitor in cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Ch | 1998 |